Convalescent plasma does not improve survival in patients hospitalized with COVID-19
1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual ...
Tag: B.1.1.7 variant
Nationwide vaccination campaign with BNT162b2 (Pfizer–BioNTech) mRNA vaccine reports high immunogenicity across all age groups
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their ...
ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The ...